Ideaya Biosciences Inc
Research Ideaya Biosciences Inc (IDYA) on Bullrun: market cap USD 3.73B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIDYA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.73B
- Financial periodQ2 2026
- RevenueUSD 8.86M
- Net income-USD 112.45M
- Free cash flow-USD 89.08M
Valuation Snapshot
latest market cap is USD 3.73B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 218.71M | -USD 113.70M | -USD 73.47M | n/a | -1.28 | USD 112.83M | USD 27.91M | USD 1.02B |
| FY2024 | USD 7.00M | -USD 274.48M | -USD 251.44M | n/a | -3.36 | USD 84.38M | USD 19.17M | USD 1.06B |
| FY2023 | USD 23.39M | -USD 112.96M | -USD 117.59M | n/a | -1.96 | USD 157.02M | USD 2.87M | USD 621.09M |
| FY2022 | USD 50.93M | -USD 58.66M | -USD 90.62M | n/a | -1.42 | USD 68.63M | USD 4.36M | USD 349.46M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.73B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.04B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.22B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.29B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 874.22M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 910.92M | n/a | n/a | n/a |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ideaya Biosciences Inc's market cap?
Ideaya Biosciences Inc's market capitalization is USD 3.73B.
What does Ideaya Biosciences Inc do?
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.